SUPERNUS PHARMACEUTICALS, INC.

Effective at 8:18 a.m. Eastern Time on November 2, 2026 (the “Effective Time”), Supernus Pharmaceuticals, Inc., a Delaware corporation (“Supernus” or the “Company”), and Indivior Pharmaceuticals, Inc., a Delaware corporation (“Indivior”), completed the previously announced business combination, pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026 (the “Merger Agreement”), by and among Indivior, Artemis Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Indivior (“Merger Sub”), and Supernus. Pursuant to the Merger Agreement, Merger Sub merged with and into Supernus (the “Merger”), with Supernus continuing as the surviving corporation and becoming a wholly owned subsidiary of Indivior. In connection with, and immediately upon completion of, the Merger, Indivior was renamed “Supernus, Inc.” References to the “Combined Company” as used in this Current Report on Form 8-K shall mean Indivior, as renamed, following the closing of the Merger (the “Closing”). As a result of the Merger, the Company became a wholly owned subsidiary of the Combined Company, and shares of the Company’s common stock, par value $0.001 per share (the “Supernus Common Stock”), will cease to be listed on The Nasdaq Stock Market LLC (“Nasdaq”).